2XDE
Crystal structure of the complex of PF-3450074 with an engineered HIV capsid N terminal domain
2XDE の概要
| エントリーDOI | 10.2210/pdb2xde/pdb |
| 分子名称 | GAG POLYPROTEIN, N-METHYL-NALPHA-[(2-METHYL-1H-INDOL-3-YL)ACETYL]-N-PHENYL-L-PHENYLALANINAMIDE (3 entities in total) |
| 機能のキーワード | aids, viral protein |
| 由来する生物種 | HUMAN IMMUNODEFICIENCY VIRUS 1 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 33286.03 |
| 構造登録者 | Brown, D.G.,Irving, S.L.,Anderson, M.,Bazin, R. (登録日: 2010-04-30, 公開日: 2010-12-22, 最終更新日: 2024-05-01) |
| 主引用文献 | Blair, W.S.,Pickford, C.,Irving, S.L.,Brown, D.G.,Anderson, M.,Bazin, R.,Cao, J.,Ciaramella, G.,Isaacson, J.,Jackson, L.,Hunt, R.,Kjerrstrom, A.,Nieman, J.,Patick, A.K.,Perros, M.,Scott, A.D.,Whitby, K.,Wu, H.,Butler, S.L. HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention. Plos Pathog., 6:E1220-, 2010 Cited by PubMed Abstract: Despite a high current standard of care in antiretroviral therapy for HIV, multidrug-resistant strains continue to emerge, underscoring the need for additional novel mechanism inhibitors that will offer expanded therapeutic options in the clinic. We report a new class of small molecule antiretroviral compounds that directly target HIV-1 capsid (CA) via a novel mechanism of action. The compounds exhibit potent antiviral activity against HIV-1 laboratory strains, clinical isolates, and HIV-2, and inhibit both early and late events in the viral replication cycle. We present mechanistic studies indicating that these early and late activities result from the compound affecting viral uncoating and assembly, respectively. We show that amino acid substitutions in the N-terminal domain of HIV-1 CA are sufficient to confer resistance to this class of compounds, identifying CA as the target in infected cells. A high-resolution co-crystal structure of the compound bound to HIV-1 CA reveals a novel binding pocket in the N-terminal domain of the protein. Our data demonstrate that broad-spectrum antiviral activity can be achieved by targeting this new binding site and reveal HIV CA as a tractable drug target for HIV therapy. PubMed: 21170360DOI: 10.1371/JOURNAL.PPAT.1001220 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.4 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






